Oct 17, 2023
(Podcast) Confronting Demodex blepharitis: From rude awakening to FDA-approved solutio
Peter J. McDonnell, MD Neda Shamie, MD In this podcast episode, Ophthalmology Times’ co-chief medical editors Peter J. McDonnell, MD, …
Resources
Oct 12, 2023
Wet Macular Degeneration Research Opportunity
Research Opportunity for Wet Macular Degeneration Patients currently living in The United States. This is a 60-minute web-assisted phone interview via Zoom. Compensation is $120. …
Sep 13, 2023
Researchers find link between sleep duration and development of type 2 diabetes, despite other lifestyle factors
Researchers find a link between sleep duration and the development of type 2 diabetes, despite other lifestyle factors A team …
Sep 13, 2023
Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US
David Hutton, Managing Editor, Ophthalmology Times Bausch + Lomb Corp. announced the US commercial launch of perfluorohexyloctane ophthalmic solution (Miebo) …
Sep 11, 2023
Ocular allergies and dry eye disease: Overlapping treatment options
Euin Cheong, OD Dual-purpose therapeutics help patients with both conditions.
Sep 11, 2023
Diabetics, rejoice: For some, an extra cup of coffee might be just what the doctor ordered
Diabetics, rejoice: For some, an extra cup of coffee might be just what the doctor ordered By Anastasia Climan, RDN, CD-N | Fact-checked by Barbara …
Aug 21, 2023
Regeneron Pharmaceuticals receive FDA approval for Eylea HD
August 18, 2023, EYLEA HD (AFLIBERCEPT) INJECTION 8 MG APPROVED BY FDA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (WAMD), …
Aug 14, 2023
Wet AMD Outcomes Through the Years
Aug 8, 2023
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
NEWS PROVIDED BY Astellas Pharma Inc. 04 Aug 2023, 21:24 ET IZERVAY is the only approved GA treatment with a statistically significant …
Aug 1, 2023
HealthWell Foundation Opens New Financial Assistance Fund for People Diagnosed with Type 2 Diabetes
byPRNewswire Fund Helps Underinsured Americans in Need of Medication Copayment Assistance GERMANTOWN, Md., July 31, 2023 /PRNewswire/ — The HealthWell Foundation®, an independent …
Jul 31, 2023
Matters of Vision! 2023 Elk Grove, IL
Register today before they are gone- Only 11 seats remain for the August 12th program in Elk Grove, IL. Call …
Jul 31, 2023
Minty Cucumber Salad
by: Beth Warren Beth Warren Nutrition <beth@bethwarrennutrition.com> MINTY WATERMELON CUCUMBER SALAD INGREDIENTS • 8 cups cubed seedless watermelon • 2 …
Jul 26, 2023
BREAKING NEWS: FDA approves XDEMVY for treatment of Demodex blepharitis
by: David Hutton According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis …
Jun 20, 2023
Geographic Atrophy new treatment
by: Pamela Weber, MD Island Retina We finally have a treatment for dry AMD with geographic atrophy “Syfovre”. It will be …
Jun 20, 2023
Understanding Age-Related Macular Degeneration
by Pamela Weber, MD Island Retina Dr. Weber guides you through AMD. What to look for, the different kinds and …
Jun 13, 2023
Diabetes and Oral Health
A healthy mouth is important for everyone, but high blood sugar can make it harder to keep your mouth healthy. …
Jun 12, 2023
Macular Degeneration Association Upcoming programs
Upcoming Programs- Did you know that there are 15 million people with some form of macular degeneration? Please join one …
Jun 12, 2023
Ophthalmology 360® Virtual Summit Series
Description: The Ophthalmology 360® Virtual Summit Series provides 2 days of accredited education and an excellent opportunity to learn from key opinion leaders in …
Apr 13, 2023
ICYMI: Study finds Americans over the age of 40 lack sight-saving knowledge of AMD
by: David Hutton A new survey of Americans 40 and older reveals a concerning lack of knowledge about the leading …
Apr 13, 2023
Know About The Health Benefits Of Prunes
Four to five prunes a day provide approximately 280 mg of potassium or about 12% of your daily required requirement. …
Apr 13, 2023
Target ‘Inflammaging’ to Promote Healthy Aging
by: April 11, 2023 / By Julie Poteet, OD, MS, CNS, FONS Doctors are taught that there are two types of inflammation, …
Mar 15, 2023
Seeing Clearly
By Claire Zulkey How a routine vision check can save your life Jackie Memije assumed she was just stressed out, …
Mar 15, 2023
How Melatonin Might Impact Your Eye Health
BY BETH BRADFORD Melatonin works in your brain to regulate your sleep cycle because it kicks in when there’s less light. …
Mar 15, 2023
LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data
Press Release March 15, 2023, 07:17 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) …
Mar 14, 2023
Ocugen submits NDA with FDA to initiate phase 1 clinical trial evaluating OCU200 for treatment of DME
by: David Hutton The regulatory milestone fulfills the company’s goal to file the IND for OCU200 within the first quarter …
Mar 7, 2023
MacuHealth & Macular Degeneration Association announce partnership
Press Release The Macular Degeneration Association and MacuHealth Announce Partnership BIRMINGHAM, Mich., March 07, 2023 – The Macular Degeneration …
Mar 7, 2023
Eyedaptic unveils the EYE5 glasses with EyeSwitch™
The latest model in the Eyedaptic product showcase boasts comfort without sacrificing usability and adds brand-new artificial intelligence features. Laguna …
Feb 28, 2023
February as Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month.
These conditions impact millions (AMD alone affects 196M) of individuals worldwide. This month highlights the importance of those with low vision …
Feb 28, 2023
AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW
Breaking News BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients …